Core Insights - AstraZeneca achieved a record revenue of $6.664 billion in China for 2025, marking a significant milestone in its 30-year history in the market [1] - The company plans to invest $15 billion in China by 2030 and has established a $18.5 billion collaboration with CSPC Pharmaceutical Group [1] Revenue Performance - AstraZeneca is the second-largest market for the company, with 2024 revenues reaching $54.073 billion, and China contributing $6.413 billion, a year-on-year increase of 11% [1] - In 2025, total revenue reached $58.739 billion, with China contributing $6.654 billion, accounting for 11% of total revenue, maintaining the top position among multinational pharmaceutical companies in China [1][3] Product Portfolio - Since entering the Chinese market in 1993, AstraZeneca has introduced over 40 innovative drugs, including key products in oncology and chronic disease management [3] - The inhaled budesonide suspension is the highest-selling drug in China, although its sales have declined due to policy price adjustments [3] - Osimertinib is expected to become a new flagship product in China, potentially replacing budesonide due to the large market for non-small cell lung cancer patients [3][4] Strategic Focus - AstraZeneca is focusing on a comprehensive "innovation offensive" in China, particularly in oncology, cardiovascular, renal, and metabolic disease areas [6] - The company has a robust pipeline in oncology, with several promising drugs set to launch in China, including novel AKT inhibitors and TROP2 ADCs for breast cancer treatment [6] - The pipeline also includes treatments for chronic diseases and rare diseases, addressing the diverse needs of the Chinese market [7][8] Investment Plans - AstraZeneca's $15 billion investment will focus on expanding drug manufacturing and R&D capabilities, particularly in cell therapy and radiolabeled drug conjugates [12][13] - The company has made 23 collaborations in China since 2021, totaling over $40 billion, with a significant focus on oncology and chronic disease treatments [9][12] Market Positioning - AstraZeneca aims to leverage China's scientific and manufacturing strengths to provide cutting-edge treatment solutions, positioning itself as a leader in cell therapy capabilities [13] - The company has established global strategic R&D centers in Beijing and Shanghai and operates multiple production bases across China [13][14] Conclusion - AstraZeneca's deep integration into the Chinese market signifies a shift from merely selling products to becoming a core participant in China's healthcare ecosystem, evolving into a global innovation center rooted in China [15]

【同源康医药】十倍潜力，TY9591新药申请获受理 事件：2月6日， 国家药品监督管理局药品审评中心数据显示，公司甲磺酸艾多替尼片(TY9591)申请已获受理，受 理号为CXHS2600026。 EGFR突变在NSCLC亚裔患者中占比达50%，且#携带EGFR突变患者3年累积脑转移发生率64%，显著高于其他亚 型。 国内2024年三代EGFR市场约180亿元（三代EGFR基本 【同源康医药】十倍潜力，TY9591新药申请获受理 事件：2月6日， 国家药品监督管理局药品审评中心数据显示，公司甲磺酸艾多替尼片(TY9591)申请已获受理，受 理号为CXHS2600026。 EGFR突变在NSCLC亚裔患者中占比达50%，且#携带EGFR突变患者3年累积脑转移发生率64%，显著高于其他亚 型。 国内2024年三代EGFR市场约180亿元（三代EGFR基本已取代一代、二代产品市场），且市场扔持续增长。 #三代EGFR尚无针对脑转移药物获批。 TY9591关键Ⅱ期试验#头对头击败奥希替尼。 同源康医药TY-9591击败奥希替尼，已经预定了百亿单品的市场地位。 此前TY9591纳入CDE优先审评名单，NDA受理后有望于2 ...

同源康医药是一家专注于肿瘤创新药物研发的生物医药公司。由吴豫生于2017年11月发起创办，其现任 公司董事长、总裁，拥有超20年医药行业从业经验，曾任职于美国跨国药企先灵葆雅新药研发中心，具 备深厚的新药研发与项目管理能力。公司于2024年8月登陆港交所，开启研发与商业化协同发展新阶 段，始终致力于通过自主研发与全球合作，为患者提供突破性治疗方案。目前已有多个创新项目处于临 床或临床前开发阶段，形成了丰富的产品管线布局。 同源康医药近日迎来发展里程碑。公司宣布，其自主研发的针对非小细胞肺癌（NSCLC）脑转移的甲 磺酸艾多替尼片（TY-9591）新药上市申请（NDA）已获得国家药监局药审中心受理。 该药作为首个针对肺癌脑转移的新一代EGFR-TKI抑制剂，凭借差异化优势备受市场关注。公司管线布 局及差异化价值传递，也成为投资者聚焦的核心。 截至2月6日收盘，同源康医药股价为12.9港元/股，市值为49亿港元。 纳入优先审评阶段 产品上市进程提速 据介绍，甲磺酸艾多替尼片是已上市同类药物奥希替尼的氘代产品，通过技术改良，可减少药物有毒代 谢物AZ5104的产生，这一技术优化使得甲磺酸艾多替尼片能够以160mg的 ...

Core Viewpoint - The company has received acceptance for the New Drug Application (NDA) of its investigational drug, TY-9591, by the National Medical Products Administration (NMPA) in China, indicating a significant step towards potential market approval for treating advanced non-small cell lung cancer (NSCLC) with specific genetic mutations [1][2]. Group 1: Drug Development and Clinical Trials - TY-9591 is a deuterated derivative of Osimertinib, demonstrating high bioavailability and effective brain penetration [1]. - The NDA application targets adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions (19DEL) or exon 21 (L858R) mutations, particularly those with CNS metastases [1]. - Phase I (TYKM1601101) and Phase II (TYKM1601201) clinical trial data indicate excellent intracranial and overall response rates in NSCLC patients with brain metastases, showcasing significant clinical benefits and addressing unmet medical needs [1]. - Key Phase II clinical trial data (TYKM1601202) further confirm superior efficacy compared to Osimertinib, particularly in terms of intracranial response rates and overall clinical benefits [1]. Group 2: Clinical Value and Advantages - TY-9591 exhibits enhanced clinical value and advantages over Osimertinib in terms of chemical structure, pharmacological action, clinical efficacy, safety, and resistance mechanism analysis [2]. - The drug is expected to significantly improve disease prognosis for patients with EGFR mutation lung cancer and brain metastases [2].

Core Viewpoint - The company has received acceptance from the National Medical Products Administration (NMPA) for the New Drug Application (NDA) of its investigational drug, TY-9591, which is a deuterated derivative of Osimertinib, targeting advanced or metastatic non-small cell lung cancer (NSCLC) patients with specific EGFR mutations [1][2] Group 1: Drug Development and Clinical Trials - TY-9591 is designed for first-line treatment of adult patients with locally advanced or metastatic NSCLC who have EGFR exon 19 deletions (19DEL) or exon 21 (L858R) mutations, along with CNS metastases [1] - Phase I (TYKM1601101) and Phase II (TYKM1601201) clinical trial data have shown excellent intracranial and overall response rates in NSCLC patients with brain metastases, indicating significant clinical benefits and addressing unmet medical needs [1] - Key Phase II clinical trial data (TYKM1601202) further confirms the superior efficacy of TY-9591 over Osimertinib in terms of intracranial response rates and clinical benefits [1] Group 2: Clinical Value and Advantages - As a deuterated compound of Osimertinib, TY-9591 demonstrates enhanced clinical value and advantages across various aspects, including chemical structure, pharmacological action, clinical efficacy, safety, and resistance mechanism analysis [2] - The drug shows a significant improvement in disease prognosis for patients, highlighting its potential impact on treatment outcomes [2]

Core Viewpoint - The company has received acceptance for the New Drug Application (NDA) of its investigational drug, TY-9591, by the National Medical Products Administration (NMPA) in China, indicating a significant step towards potential market approval for treating advanced non-small cell lung cancer (NSCLC) with specific mutations [1][2]. Group 1: Drug Development and Clinical Trials - TY-9591 is a deuterated derivative of Osimertinib, demonstrating high bioavailability and effective brain penetration [1]. - The NDA application targets adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions (19DEL) or exon 21 (L858R) mutations, particularly those with CNS metastases [1]. - Phase I (TYKM1601101) and Phase II (TYKM1601201) clinical trial data indicate excellent intracranial and overall response rates in NSCLC patients with brain metastases, fulfilling unmet clinical needs [1]. - Key Phase II clinical trial data (TYKM1601202) further confirm the superior efficacy of TY-9591 over Osimertinib in terms of intracranial response rates and clinical benefits [1]. Group 2: Clinical Value and Advantages - TY-9591 shows significant clinical value and advantages in terms of chemical structure, pharmacological action, clinical efficacy, safety, and resistance mechanism analysis [2]. - The drug is expected to improve disease prognosis significantly for patients with EGFR mutation lung cancer and brain metastases [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 自願公告 甲磺酸艾多替尼片（TY-9591片）的新藥上市申請 獲國家藥品監督管理局受理 浙江同源康醫藥股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願刊 發，以告知本公司股東及潛在投資者有關本集團最新業務發展的資料。 本公司董事會（「董事會」）欣然宣佈，本公司在研1類新藥甲磺酸艾多替尼片 （TY-9591片）的新藥上市申請（「NDA」）被國家藥品監督管理局（「NMPA」）藥品 審評中心（「CDE」）受理。現將相關情況公告如下： 甲磺酸艾多替尼片（TY-9591片）為奧希替尼的氘代物，生物利用度高，入腦效 果好，本次NDA註冊申報適應症為具有EGFR外顯子19缺失(19DEL)或外顯子 21(L858R)置換突變，並伴有CNS轉移的局部晚期或轉移性NSCLC成人患 ...

自愿披露HYP-6589片联合用药 获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 近日，四川汇宇制药股份有限公司（以下简称"公司"）全资子公司四川汇宇海玥医药科技有限公司（以 下简称"汇宇海玥"）收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，化学创新药 HYP-6589片（项目研发代号为"HY-0006"）用于开展与奥希替尼联合治疗靶点驱动基因阳性的晚期非小 细胞肺癌的临床试验获得批准。现将相关情况公告如下： 一、药品基本情况 药品名称：HYP-6589片 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688553 证券简称：汇宇制药 公告编号：2026-005 四川汇宇制药股份有限公司 注册分类：化学药品1类创新药 申请事项：境内生产药品注册临床试验 受理号：CXHL2501288；CXHL2501289； 适应症：拟用于与奥希替尼联合治疗靶点驱动基因阳性的晚期非小细胞肺癌。 申请人：四川汇宇海玥医药科技有限公司 审批结论：根据《中华人民共和国药品管理法》及 ...

Group 1 - The core announcement is that Huayu Pharmaceutical's wholly-owned subsidiary, Sichuan Huayu Haiyue Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of the innovative chemical drug HYP-6589 tablets, which is intended for use in combination with Osimertinib for treating advanced non-small cell lung cancer with target-driven gene positivity [2] Group 2 - The clinical trial approval is a significant step for the company in advancing its research and development efforts in oncology [2] - HYP-6589, also referred to by its research and development code "HY-0006," represents a potential new treatment option in the competitive oncology market [2] - The approval highlights the company's commitment to developing innovative therapies for serious health conditions [2]

每经AI快讯，汇宇制药1月28日晚间发布公告称，近日，四川汇宇制药股份有限公司全资子公司四川汇 宇海玥医药科技有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，化学创新 药HYP-6589片用于开展与奥希替尼联合治疗靶点驱动基因阳性的晚期非小细胞肺癌的临床试验获得批 准。 每经头条（nbdtoutiao）——从极寒测试到万套装车！半固态电池今年有望搭载多款新车：各大厂商摩 拳擦掌，动力电池技术迎来迭代年 （记者 王晓波） ...